๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites๐Ÿ“ Santa Rosa๐Ÿ“ Hartford๐Ÿ“ Washington D.C. VM Oncology, LLC ยท Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT07680764Phase 274 sites๐Ÿ“ Washington D.C.๐Ÿ“ Athens๐Ÿ“ Lexington Bristol-Myers Squibb ยท Tests: Pumitamig, Imzokitug, Pemetrexed, Cisplatin, Carboplatin A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043Phase 1, Phase 213 sites๐Ÿ“ Grand Rapids๐Ÿ“ St Louis๐Ÿ“ Pittsburgh AstraZeneca ยท Tests: AZD6750, rilvegostomig A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors NCT06747585Phase 1, Phase 241 sites๐Ÿ“ Scottsdale๐Ÿ“ Fullerton๐Ÿ“ Los Angeles Alentis Therapeutics AG ยท Tests: ALE.P02, Pembrolizumab A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674Phase 117 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ San Francisco Nurix Therapeutics, Inc. ยท Tests: NX-1607, Paclitaxel A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC NCT06627647Phase 3301 sites๐Ÿ“ Mobile๐Ÿ“ Chandler๐Ÿ“ Phoenix AstraZeneca ยท Tests: Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07155187Phase 2, Phase 3117 sites๐Ÿ“ Springdale๐Ÿ“ Duarte๐Ÿ“ Irvine AbbVie ยท Tests: Telisotuzumab Adizutecan, Standard of Care, Osimertinib Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors NCT06975410Phase 1, Phase 24 sites๐Ÿ“ Seoul๐Ÿ“ Seoul๐Ÿ“ Seoul Yuhan Corporation ยท Tests: YH32364 Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer NCT06899126Phase 3246 sites๐Ÿ“ Anchorage๐Ÿ“ Fountain Valley๐Ÿ“ Los Angeles Daiichi Sankyo ยท Tests: Trastuzumab Deruxtecan, pembrolizumab, Pemetrexed, Platinum Chemotherapy A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors NCT06465069Phase 139 sites๐Ÿ“ Duarte๐Ÿ“ La Jolla๐Ÿ“ Los Angeles Eli Lilly and Company ยท Tests: LY4052031, Pembrolizumab A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors NCT07887971Phase 11 site๐Ÿ“ Miami Aktis Oncology, Inc. ยท Tests: [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors NCT07589205Phase 11 site๐Ÿ“ Tianjin Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. ยท Tests: Drug: IBI3028 Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC NCT04686305Phase 191 sites๐Ÿ“ Duarte๐Ÿ“ Newport Beach๐Ÿ“ Orange AstraZeneca ยท Tests: T-DXd, Durvalumab, Cisplatin, Carboplatin, Pemetrexed Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations NCT07336732Phase 21 site๐Ÿ“ Guangzhou Avistone Biotechnology Co., Ltd. ยท Tests: PLB1004 Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rฮฑ Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer NCT05267626Phase 1, Phase 217 sites๐Ÿ“ Miami๐Ÿ“ Grand Rapids๐Ÿ“ Minneapolis Aulos Bioscience, Inc. ยท Tests: AU-007, Aldesleukin, Avelumab, Nivolumab A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression NCT06682793Phase 1, Phase 210 sites๐Ÿ“ Gilbert๐Ÿ“ La Jolla๐Ÿ“ Los Angeles A2 Biotherapeutics Inc. ยท Tests: A2B395, xT CDx with HLA-LOH assay A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive NCT06930794Phase 32 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou Beijing Pearl Biotechnology Limited Liability Company ยท Tests: Vebreltinib combined with platinum-based doublet chemotherapy., platinum-based doublet chemotherapy. A Study of SH009 Injection in Patients With Advanced Solid Tumors. NCT07390838Phase 11 site๐Ÿ“ Shanghai Nanjing Sanhome Pharmaceutical, Co., Ltd. ยท Tests: SH009 A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07005102Phase 2, Phase 365 sites๐Ÿ“ Chandler๐Ÿ“ Duarte๐Ÿ“ Irvine AbbVie ยท Tests: Standard of Care, Telisotuzumab Adizutecan, Osimertinib (Osi), Cisplatin, Carboplatin Study of XB010 in Subjects With Solid Tumors NCT06545331Phase 120 sites๐Ÿ“ Irvine๐Ÿ“ Los Angeles๐Ÿ“ Washington D.C. Exelixis ยท Tests: XB010, Pembrolizumab A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors NCT06561685Phase 133 sites๐Ÿ“ Santa Monica๐Ÿ“ Aurora๐Ÿ“ Denver Eli Lilly and Company ยท Tests: LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status NCT07034391Phase 21 site๐Ÿ“ Shenyang China Medical University, China ยท Tests: denosumab combined anti-PD-1 inhibitor with chemotherapy 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors NCT07189871Phase 1, Phase 25 sites๐Ÿ“ Dothan๐Ÿ“ Grand Rapids๐Ÿ“ Omaha Radiopharm Theranostics, Ltd ยท Tests: 177Lu-BetaBart, BetaBart + unlabeled BetaBart Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %. NCT05937906Phase 1, Phase 21 site๐Ÿ“ Dijon Centre Georges Francois Leclerc ยท Tests: Phase I - Mirdametinib - Level 1, Phase II - Mirdametinib, Phase I - Mirdametinib - Level 2, Phase I - Mirdametinib - Lโ€ฆ A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) NCT06875310Phase 3317 sites๐Ÿ“ Birmingham๐Ÿ“ Springdale๐Ÿ“ Fullerton Mirati Therapeutics Inc. ยท Tests: Adagrasib, Pembrolizumab, Carboplatin, Pemetrexed, Placebo Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC โ‰ฅ 50%) and Without Actionable Genomic Alterations NCT06357533Phase 3290 sites๐Ÿ“ Anchorage๐Ÿ“ Tucson๐Ÿ“ Little Rock AstraZeneca ยท Tests: Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC NCT07178795Phase 31 site๐Ÿ“ Guangzhou Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-M07D1, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer NCT06799065Phase 1, Phase 211 sites๐Ÿ“ Aurora๐Ÿ“ Sarasota๐Ÿ“ Detroit Accent Therapeutics ยท Tests: ATX-295, ATX-295 and bevacizumab (or biosimilar) Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations NCT07291037Phase 3206 sites๐Ÿ“ Chandler๐Ÿ“ Gilbert๐Ÿ“ Goodyear AstraZeneca ยท Tests: Datopotamab deruxtecan (Dato-DXd), Docetaxel Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors NCT07030257Phase 1, Phase 213 sites๐Ÿ“ Denver๐Ÿ“ Orlando๐Ÿ“ Grand Rapids Tasca Therapeutics ยท Tests: CP-383
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy